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Simple Summary: Neoantigens are novel proteins presented on the cell surface and derived from the
accumulation of somatic mutations in tumor cells. They can be recognized by the immune system and
may play a crucial role in boosting immune responses against tumor cells. The impact of neoantigen
expression and T-cell activation status on overall survival was investigated in a breast cancer cohort.
We found that high neoantigen expression and T-cell activation status was correlated with improved
patient survival in the study population. This result supports that neoantigens are promising to serve
as immunogenic agents for immunotherapy in breast cancer.
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Abstract: Neoantigens are derived from tumor-specific somatic mutations. Neoantigen-based synthesized peptides have been under clinical investigation to boost cancer immunotherapy efficacy.
The promising results prompt us to further elucidate the effect of neoantigen expression on patient
survival in breast cancer. We applied Kaplan–Meier survival and multivariable Cox regression
models to evaluate the effect of neoantigen expression and its interaction with T-cell activation on
overall survival in a cohort of 729 breast cancer patients. Pearson’s chi-squared tests were used to
assess the relationships between neoantigen expression and clinical pathological variables. Spearman correlation analysis was conducted to identify correlations between neoantigen expression,
mutation load, and DNA repair gene expression. ERCC1, XPA, and XPC were negatively associated
with neoantigen expression, while BLM, BRCA2, MSH2, XRCC2, RAD51, CHEK1, and CHEK2 were
positively associated with neoantigen expression. Based on the multivariable Cox proportional
hazard model, patients with a high level of neoantigen expression and activated T-cell status showed
improved overall survival. Similarly, in the T-cell exhaustion and progesterone receptor (PR) positive
subgroups, patients with a high level of neoantigen expression showed prolonged survival. In
contrast, there was no significant difference in the T-cell activation and PR negative subgroups. In
conclusion, neoantigens may serve as immunogenic agents for immunotherapy in breast cancer.
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1. Introduction

This article is an open access article

DNA damage and genetic mutations accumulate during cancer development [1,2].
Somatic mutations in tumor cells may function as neoantigens which consequently elicit immune response against the tumor. Neoantigens are often recognized as foreign by adaptive
immune cells [3] and demonstrate high immunogenicity [4]. The host immune system’s
inbuilt ability to distinguish foreign proteins can induce the immune response and destruct
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malignant T-cells [3,5]. Neoantigens are processed and presented by major histocompatibility complex (MHC) molecules, which are then recognized by T-cell receptors [6,7]. CD4+
and CD8+ T-cells are subsequently activated to evoke cytotoxic T lymphocyte responses to
eliminate tumor cells [6,7]. As ideal immunotherapeutic targets, neoantigens have shown
great promise in various human malignancies and significantly reduce autoimmunity
risk with minimally assured immune tolerance [8]. Therefore, patient-specific neoantigen
is presumed to enhance the efficacy of cancer immunotherapy and serve as a beneficial
predictor of cancer prognosis in clinical trials on immunotherapeutic checkpoint inhibitors
or vaccines [9].
CD8+ T-cell exhaustion and enhanced regulatory T-cell function are important in
immune editing and escape [10]. Effector CD8+ T-cell activation, one of the critical components in the anti-tumor immunity, has been shown to be positively associated with
neoantigens and impact patient survival [10,11]. Immunotherapy may fail for multiple
reasons including lack of T-cells that are capable to recognize neoantigens, suppression of
such T-cells [9], and insufficient amount of expressed neoantigens. A series of inhibitory
molecules are allied to effector CD8+ T-cell exhaustion, causing tumor cells to escape
from immune surveillance [11,12]. Immune checkpoints, such as cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), transmit
negative signals to CD8+ T-cell and reduce tumor-infiltrating lymphocytes during the
anti-tumor process [13–15]. Patients with high T-cell activation scores have prolonged survival in breast cancer [10]. Deficient DNA repair yields genomic instability and promotes
clinical responses to immune checkpoint inhibitors (ICIs). Application of ICIs has been
approved to treat the subgroup of patients with cancer resulting from genomic instability.
Several DNA repair pathways have been found to confer more neoantigens [16]. Therefore,
investigating the relationship between neoantigens and DNA repair pathways is likely to
provide new insights in immunotherapy.
Studies have proposed association of neoantigen with survival in cancer patients [17,18].
There exists positive correlation between predicted neoantigen load and breast cancer
survival [6]. In this study, we aim to study whether neoantigen expression, together with
T-cell activation status, affects patient survival in breast cancer. We also explored the
relationship between neoantigen expression and DNA repair genes in breast cancer. To
our knowledge, this is the first study to illuminate that neoantigen expression is positively
associated with improved breast cancer survival.
2. Materials and Methods
2.1. Study Subjects and Data Sources
This study included 1081 female patients diagnosed with primary breast cancer. Clinical data on the patients were obtained from The Cancer Genome Atlas (TCGA) breast invasive carcinoma study (http://www.cbioportal.org/, assessed on 1 July 2018) The somatic
mutation data on 90,969 mutant sites were downloaded from Genomic Data Commons
(GDC) data portal (https://portal.gdc.cancer.gov/; assessed on 26 September 2019). The
normalized RNA sequencing data which provide gene expression levels of 60,483 mRNA
transcripts were downloaded from GDC data portal. All data were downloaded using
an R package ‘TCGAbiolink’ [19]. The binding affinities between mutant peptides and
HLA alleles, as well as the affinities with the corresponding wild-type peptides, were
obtained from a previous study in which the binding affinities were reported using two
measures, half maximal inhibitory concentration (IC50 ) value and percentile rank score [20].
The IC50 value reports a direct binding affinity prediction, and the percentile rank score
reports relative binding affinity with a specific HLA allele compared to a random peptide.
Mutant peptide with IC50 < 500 nM or percentile rank score ≤ 2 is commonly considered
as a potential neoantigen, indicating a strong bind to HLA [20–23]. After merging all data
together, clinical information, somatic mutations, mRNA expression, and peptide binding
affinities of 729 patients were available for further analysis.
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2.2. Statistical Analysis
Neoantigens were predicted based on peptide-HLA binding affinities. A mutant
peptide is considered as a neoantigen if (1) the predicted binding affinity with the patient’s
HLA alleles satisfies that IC50 < 500 nM or percentile rank score ≤ 2, and (2) the binding
affinity of the corresponding wild-type peptide satisfies that IC50 ≥ 500 nM or percentile
rank score > 2 [22]. Several pathogenic variants—such as BRCA1/2, KRAS, NRAS, PTEN,
TP53, and PALB2—tend to increase breast cancer risk. Individuals who carry the susceptibility alleles at these variants are more likely to develop breast cancer. In this study,
we excluded these pathogenic genes for neoantigen prediction to reduce false-positive
causality [24]. For each mutant peptide, neoantigen expression was the expression level
of the gene where the mutant resides if it was predicted as a neoantigen. An individual’s
neoantigen expression was the total gene expression levels across all predicted neoantigens.
Pearson’s chi-squared tests were used to assess the associations between neoantigen
expression and clinical variables including estrogen receptor (ER) status, progesterone
receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, molecular
subtype, disease stage, and histological type. Binary neoantigen expression level, high
or low, was defined based on the cutoff value of neoantigen expression determined by
an algorithm to maximally separate the survival curves between the two groups using
an R package ‘survminer’. Spearman correlation analysis was conducted to evaluate the
correlations between neoantigen expression, mutation load, and the expression levels of
24 DNA repair genes, APEX1, ATM, BLM, BRCA1, BRCA2, ERCC1, ERCC4, ERCC6, FANCG,
MLH1, MSH2, MSH3, MUTYH, OGG1, RPAP1, XPA, XPC, XRCC1, XRCC2, XRCC3, XRCC4,
RAD51, CHEK1, and CHEK2 [7,25–28]. Bonferroni adjustment was used to correct for
multiple hypothesis testing.
A weighted T-cell activation score was calculated for each patient based on 13 genes
that are related to T-cell activation status as described previously [10]. We further divided
patients into two groups, activation and exhaustion. Multivariable Cox proportional hazard
models were used to evaluate the relationship between neoantigen expression and overall
survival. Patient’s age at diagnosis, ER status, disease stage, histology, and T-cell activation
status were included as covariates in the models to obtain adjusted hazard ratios (HRs) with
95% confidence intervals (CIs). The effect of neoantigen expression on overall survival was
further assessed in each subgroup stratified by the T-cell activation status, ER status, and
PR status, respectively. In all statistical analyses, results were considered significant when
p-values were less than 0.05. All analyses were performed in R (https://www.r-project.
org/; version 3.5.1, updated on 1 March 2019)
3. Results
3.1. Clinical and Pathologic Characteristics of Patients
Characteristics of the 729 breast cancer patients are displayed in Table 1. The average
age at diagnosis was 57.7 (range 26–90) years old. Among the 709 patients with disease
stage information, 17.6% (n = 125) were diagnosed at stage I, 57.6% (n = 408) were at stage II,
and 24.8% (n = 176) were diagnosed at an advanced stage (III or IV). Among the 691 patients
with a known ER status, 77.1% (n = 533) were ER-positive. Among the 689 patients with a
known PR status, 68.4% (n = 471) were PR-positive. Among the 498 patients with a known
HER2 status, 23.5% (n = 117) were HER2-positive. All patients had malignant breast cancer
with the predominant histological type of ductal carcinoma (83.0%, n = 604), followed
by lobular (8.5%, n = 62), mix (6.0%, n = 44), and other (2.5%, n = 18). 495 patients had
molecular subtype information available: 79.4% (n = 393) luminal, 14.3% (n = 71) basal-like,
and 6.3% (n = 31) HER2-enriched. The average length of follow-up in the 729 patients was
42.8 (range: 0–282.7) months and 112 patients died during the follow-up period.
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Table 1. Characteristics of 729 breast cancer patients.
Variable

N

ER
Negative
Positive
PR
Negative
Positive
HER2
Negative
Positive
Molecular subtype
Luminal
Basal-like
HER2-enrich
Stage
I
II
III & IV
Histology
Ductal
Lobular
Mix
Other
Death
No
Yes

691
158
533
689
218
471
498
381
117
495
393
71
31
709
125
408
176
728
604
62
44
18
729
617
112

84.6
15.4

N

Mean (Range)

729
729

57.7 ± 13.1 (26–90)
42.8 (0–282.7)

1,

Age (mean ± SD years)
Follow-up (months)
1

%
22.9
77.1
31.6
68.4
76.5
23.5
79.4
14.3
6.3
17.6
57.6
24.8
83.0
8.5
6.0
2.5

SD: standard deviation.

3.2. Correlation between Neoantigen Expression and Clinical Pathological Variables
Neoantigen expression was calculated using the expression values of all predicted
neoantigens for each patient. The median of neoantigen expression was 57.38 (range:
0–7038.03). A cutoff value of 16.10 was chosen to classify the patients into two groups:
569 patients (78.1%) in the high neoantigen expression group, and 160 patients (21.9%) in
the low neoantigen expression group. Correlations between neoantigen expression and
clinical pathological variables—including the ER status, PR status, HER2 status, molecular
subtype, disease stage, and histological type—were evaluated (Table S1). Neoantigen
expression was significantly associated with the ER status (p = 0.016), PR status (p = 0.006),
molecular subtype (p = 0.004), and disease stage (p = 0.016). There was a borderline
significant association between neoantigen expression and the HER2 status (p = 0.073).
Since ER- tumors are more immunogenic compared with ER+ tumors [29], we found that
the proportion of patients with high neoantigen expression in the ER- group is significantly
higher than that in the ER+/PR+ group (85.4% vs. 75.3%, p = 0.011).
3.3. Correlation between Neoantigen Expression, Mutation Load, and DNA Repair Genes
Correlations between the expression levels of 24 DNA repair genes and neoantigen
expression, mutation load, as well as the expression on the most shared neoantigens were
assessed (Table S2). The most shared neoantigens were defined as genes on which at least
five patients had predicted neoantigens. P-values were adjusted by Bonferroni correction
for multiple testing (Figure 1). We identified three negatively correlated genes with neoantigen expression: ERCC1 (r = −0.14, p = 4.95 × 10−3 ), XPA (r = −0.18, p = 1.19 × 10−5 ), and
XPC (r = −0.17, p = 7.58 × 10−5 ). They were also negatively correlated with mutation load:
ERCC1 (r = −0.16, p = 1.99 × 10−4 ), XPA (r = −0.32, p < 5.28 × 10−15 ), and XPC (r = −0.35,
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3.4. Association of Neoantigen Expression with Patient Survival
Correlation between neoantigen expression and overall survival was evaluated using
Kaplan–Meier (KM) survival curves. The median survival was 129.5 (95% CI: 113.7−∞)
months for the high neoantigen expression group, and 97.4 (95% CI: 82.8−∞) months for
the low neoantigen expression group (Figure 2). There was a difference of 32.1 months
in median survival between the two groups. The log-rank p-value was not significant
(p = 0.180) when comparing the survival curves of the two groups. In the ER-positive
subgroup, patients with a high neoantigen expression level had better overall survival
compared to those with a low neoantigen expression level (p = 0.049, Figure 3A), while in
the ER-negative subgroup, there was no significant difference in overall survival between
the high and low neoantigen expression groups (p = 0.281, Figure 3B). In the PR-positive
subgroup, there was a borderline significant positive association between neoantigen
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Figure 3. Kaplan–Meier survival curve of neoantigen expression stratified by ER status. (A) In the
ER positive subgroup, patients with a high level of neoantigen expression had better overall survival compared to those with a low level (p = 0.049); (B) In the ER negative subgroup, there was no
7 of 15
significant difference in survival between patients in the high and low levels of neoantigen expression (p = 0.281).

Figure 4. Kaplan–Meier survival curve of neoantigen expression stratified by PR status. (A) In the
Figure 4. Kaplan–Meier survival curve of neoantigen expression stratified by PR status. (A) In the
PR positive subgroup, patients with a high level of neoantigen expression had borderline better
PR positive subgroup, patients with a high level of neoantigen expression had borderline better
overall survival compared to those with a low level (p = 0.054); (B) In the PR negative subgroup,
overall survival compared to those with a low level (p = 0.054); (B) In the PR negative subgroup, there
was no significant difference between patients in the high and low levels of neoantigen expression
(p = 0.526).

The effect of neoantigen expression on overall survival was also assessed using the
multivariable Cox regression model, adjusted for patient’s age at diagnosis, ER status,
disease stage, histology, and T-cell activation status (Table 2). A higher neoantigen expression level was significantly associated with decreased risk of mortality. The adjusted
HR was 0.61 (95% CI: 0.38–0.97, p = 0.038) for the high vs. low neoantigen expression
group. Overall, patients with a high T-cell activation score (activation, n = 184) had better
overall survival compared to those with a low T-cell activation score (exhaustion, n = 545).
The adjusted HR was 0.48 (95% CI: 0.24–0.96, p = 0.038) for the activation group vs. the
exhaustion group.
Table 2. Relationship between overall survival and neoantigen expression.
Death
Variables
Neoantigen Expression
Low
High
T-cell Activation
Exhaustion
Activation
Age
ER
Negative
Positive
Stage

HR (95% CI

1

p-Value

1.00
0.61 (0.38–0.97)

0.038

1.00
0.48 (0.24–0.96)
1.04 (1.03–1.06)

0.038
<0.001

1.00
0.53 (0.32–0.87)

0.012
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Table 2. Cont.
Death
Variables
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other
1

HR (95% CI

1

p-Value

1.00
2.64 (1.39–5.04)

0.003

1.00
0.73 (0.35–1.51)
0.93 (0.48–1.77)

0.395
0.817

CI: confidence interval.

We further investigated the relationship between survival and neoantigen expression
stratified by T-cell activation status (Table 3). In the exhaustion group, patients with a high
neoantigen expression level showed better overall survival compared to those with a low
neoantigen expression level. The adjusted HR was 0.55 (95% CI: 0.34–0.89, p = 0.016) for
the high vs. low neoantigen expression group. In contrast, among patients in the activation
group, there was no significant difference in overall survival between the high and low
neoantigen expression groups. The adjusted HR was 0.76 (95% CI: 0.08–7.44, p = 0.816) for
the high vs. low neoantigen expression group.
Table 3. Association between neoantigen expression and overall survival stratified by T-cell activation status.
Stratification
Variable

T-cell Exhaustion

T-cell Activation

1

Death
Variables
Neoantigen Expression
Low
High
Age
ER
Negative
Positive
Stage
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other
Neoantigen Expression
Low
High
Age
ER
Negative
Positive
Stage
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other

HR (95% CI 1

p-Value

1.00
0.55 (0.34–0.89)
1.04 (1.03–1.06)

0.016
<0.001

1.00
0.45 (0.27–0.75)

0.002

1.00
2.80 (1.38–5.67)

0.004

1.00
0.58 (0.25–1.30)
0.95 (0.47–1.93)

0.185
0.887

1.00
0.76 (0.08–7.44)
1.06 (1.00–1.13)

0.816
0.049

1.00
0.89 (0.18–4.34)

0.890

1.00
5.52 (0.71–42.90)

0.103

1.00
7.80 (1.00–60.59)
0.48 (0.05–4.44)

0.050
0.521

CI: confidence interval.

We also performed analysis stratified by the ER and PR status. In the ER-positive
subgroup, there was a borderline significant positive association between neoantigen
expression and overall survival (Table 4). The adjusted HR was 0.61 (95% CI: 0.36–1.04,
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p = 0.067) for the high vs. low neoantigen expression group. In the ER-negative subgroup,
there was no significant difference in overall survival between the high and low neoantigen
expression groups. The adjusted HR was 0.76 (95% CI: 0.26–2.16, p = 0.601) for the high
vs. low neoantigen expression group. In the PR-positive subgroup, patients with a high
neoantigen expression level showed better overall survival compared to those with a
low neoantigen expression level (Table 5). The adjusted HR was 0.57 (95% CI: 0.32–0.99,
p = 0.046) for the high vs. low neoantigen expression group. In contrast, among PR-negative
patients, there was no significant difference in overall survival between the high and low
neoantigen expression groups. The adjusted HR was 0.67 (95% CI: 0.24–1.84, p = 0.439) for
the high vs. low neoantigen expression group.
Table 4. Association between neoantigen expression and overall survival stratified by ER status.
Stratification
Variable

ER Positive

ER Negative

1

Death
Variables
Neo Expression
Low
High
T-cell Activation
Exhaustion
Activation
Age
Stage
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other
Neo Expression
Low
High
T-cell Activation
Exhaustion
Activation
Age
Stage
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other

HR (95% CI 1

p-Value

1.00
0.61 (0.36–1.04)

0.067

1.00
0.80 (0.34–1.89)
1.05 (1.03–1.07)

0.613
<0.001

1.00
2.56 (1.25–5.24)

0.010

1.00
0.47 (0.19–1.14)
1.01 (0.49–2.07)

0.096
0.989

1.00
0.76 (0.26–2.16)

0.601

1.00
0.32 (0.11–0.99)
1.03 (1.00–1.06)

0.048
0.061

1.00
4.93 (0.65–37.26)

0.122

1.00
4.64 (1.17–18.45)
0.61 (0.13–2.90)

0.029
0.538

CI: confidence interval.

3.5. Association of Expression of the Most Shared Neoantigens with Patient Survival
There were 47 genes that had shared neoantigens by patients ranging from 5–23. For
example, 23 (3.16%) patients had neoantigens on MUC16, also known as cancer antigen
125 (CA125), 21 (2.88%) on PCDHGC5, 19 (2.61%) on PCDHAC2, 12 (1.65%) on USH2A,
11 (1.51%) on RYR3, and 8 (1.10%) on MUC17. Correlation between the expression of the
most shared neoantigens and overall survival was evaluated using KM survival curves.
In the entire study population, patients with a high neoantigen expression level on these
genes had better overall survival compared to those with a low neoantigen expression level
(log-rank p = 0.026, Figure S1). When stratified by T-cell activation status, ER status, and
PR status, patients with a high expression level on the most shared neoantigens showed
improved overall survival in the T-cell exhaustion group (log-rank p = 0.034, Figure S2A),
ER-positive group (log-rank p = 0.049, Figure S3A), and PR-negative group (log-rank
p = 0.016, Figure S4B).
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Table 5. Association between neoantigen expression and overall survival stratified by PR status.
Stratification
Variable

PR Positive

PR Negative

1

Death
Variables
Neo Expression
Low
High
T-cell Activation
Exhaustion
Activation
Age
ER
Negative
Positive
Stage
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other
Neo Expression
Low
High
T-cell Activation
Exhaustion
Activation
Age
ER
Negative
Positive
Stage
Stage I
Stage II–IV
Histology
Ductal
Lobular
Mix or Other

HR (95% CI

1

p-Value

1.00
0.57 (0.32–0.99)

0.046

1.00
0.82 (0.29–2.36)
1.05 (1.03–1.07)

0.720
<0.001

1.00
0.85 (0.11–6.38)

0.876

1.00
2.45 (1.15–5.20)

0.020

1.00
0.46 (0.19–1.14)
0.97 (0.45–2.10)

0.095
0.941

1.00
0.67 (0.24–1.84)

0.439

1.00
0.45 (0.17–1.16)
1.03 (1.00–1.06)

0.096
0.036

1.00
0.63 (0.29–1.38)

0.247

1.00
3.73 (0.88–15.91)

0.075

1.00
3.25 (0.92–11.55)
0.77 (0.22–2.69)

0.068
0.685

CI: confidence interval.

The impact of the expression of the most shared neoantigens on overall survival was
also assessed using the multivariable Cox regression model, adjusted for patient’s age at
diagnosis, ER status, disease stage, histology, and T-cell activation status (Tables S3–S5).
High neoantigen expression was significantly associated with decreased risk of mortality in
the entire sample (adjusted HR = 0.30, 95% CI: 0.11–0.82, p = 0.019) and in the ER-positive
group (adjusted HR = 0.28, 95% CI: 0.09–0.90, p = 0.033).
4. Discussion
Neoantigens were found to be a prognostic factor for overall survival of patients with
ovarian cancer [30] and melanoma [31]. Neoantigen vaccines have shown encouraging
responses to immunotherapy in clinical trials on melanoma [32] and glioblastoma [33].
Predicted neoantigen load had better prognostic potential than tumor mutation load in
the TCGA breast cancer cohort [6]. In this study, we investigated a cohort of 729 patients
with breast cancer in TCGA to assess the relationships between neoantigen expression and
clinical pathological variables, DNA repair genes, and patient survival.
Immune modulation showed limited efficacy among hormone receptor positive breast
cancer patients [34]. In this study, we found that the proportion of patients with high
neoantigen expression in the ER-positive group is lower than that in the ER-negative group
(76.0% vs. 85.4%, p = 0.016). Similar pattern was observed when comparing the PR-positive
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and PR-negative groups (75.2% vs. 84.9%, p = 0.006). Among the three molecular subtypes,
the proportion of patients with high neoantigen expression was 77.4% for Luminal, 90.1%
for Basal-like, and 93.5% for HER2-enrich subtype. Our results suggest that neoantigen
expression varied across hormone receptor status and molecular subtype of breast cancer.
Damage to DNA gives rise to potentially harmful mutations in the genome and
blockage of transcription for cell cycle arrest and checkpoints. DNA repair systems are
essential for the maintenance of genome integrity. Although defects in DNA repair lead
to large amount of mutations, high mutation load results in high neoantigen load [35]
and hence high neoantigen expression may lead to greater immunogenicity. We identified
three DNA repair genes, ERCC1, XPA, and XPC, that were negatively correlated with
tumor mutation load and neoantigen expression, suggesting that dysregulation of DNA
repair pathways may promote genome instability and increase the accumulation of DNA
lesions and mutations in tumorigenesis [36]. XPC was negatively associated with the
expression of the most shared neoantigens. ERCC1 and XPA increase the risk of breast
cancer [37,38]. XPC polymorphisms are associated with higher susceptibility of breast
cancer during the nucleotide excision repair (NER) process [39]. We also found seven
DNA repair genes—BLM, BRCA2, MSH2, XRCC2, RAD51, CHEK1, and CHEK2—that
were positively associated with tumor mutation load and neoantigen expression. Among
them, BLM and CHEK2 were positively correlated with the expression of the most shared
neoantigens. Germline mutations in BRCA1 and BRCA2 account for around 25% of familial
breast cancer clustering [40–42] and 5–10% risk of all breast cancer cases [43]. MSH2 loss
may result in advanced breast cancer and its mutations are involved in the development
of early-onset breast cancer in the Lynch syndrome family [37,44,45]. Single nucleotide
polymorphisms on XRCC2 influence breast cancer risk and survival [46]. Pathogenetic
mutations or variants in CHECK2 and RAD51 have been reported to increase the risk of
breast cancer [47]. RAD51 binds DNA at the damage site for homologous recombination
repair. Overexpression of RAD51 leads to increased homologous recombination and
promotes genomic instability with an increased prevalence of mutations [48]. In breast
cancer, RAD51 is overexpressed due to excessive transcription and reduced methylation
of the gene. The mutation or loss of the tumor suppressor gene p53 also contributes to
high RAD51 expression [48,49]. CHEK1 encodes a protein kinase that coordinates the DNA
damage response and cell cycle checkpoint response. Overexpression of CHEK1 activates
the cell cycle and MAPK signaling pathways which were reported to be related to breast
cancer onset and development. The activation of the MAPK pathway also plays a role
in cell proliferation, cell growth, and breast cancer migration [50–52]. CHEK2 is another
checkpoint gene responsible for regulating cell cycle in the presence of DNA damage.
Mutations in this gene prevent the activation of the tumor suppressor gene p53, leading
to an accumulation of mutations in the genome and the proliferation of tumor cells [53].
Overexpression of BLM mRNA was associated with poor breast cancer-specific survival
and BLM protein also influenced survival, suggesting that BLM is a promising biomarker
in breast cancer [54].
Our results demonstrated that high neoantigen expression and T-cell activation is
associated with decreased mortality risk. The prognostic effect of T-cell activation status
in breast cancer was reported in a previous study [10]. Our study was consistent with the
finding that activated T-cell status is associated with improved overall survival in breast
cancer patients. CD8+ cytotoxic T-cells recognize the neoantigens of peptide-MHC class I
molecule complexes that were presented on the cell surface and promote patient survival.
Our findings confirmed that neoantigens facilitated the anti-tumor immune response and
improved the overall outcome. In the T-cell exhaustion group, improved overall survival
was observed in patients with high neoantigen expression. However, no significant impact
of neoantigen expression was found in the T-cell activation group. Such findings suggest
that neoantigen expression affect overall survival of breast cancer patients differently given
disparate T-cell status. Patients with high level of neoantigen expression survived longer
than those with low level of neoantigen expression in ER-positive breast cancer.
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In our study, the neoantigens shared by most breast cancer patients (23 out of 729)
were MUC16/CA125. MUC16 is overexpressed in breast cancer tumors and associated with
disease stages [55]. It increases breast cancer cell proliferation and inhibits tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) [55]. Long-term survivors of pancreatic
ductal adenocarcinoma (PDAC) are enriched in MUC16/CA125 neoantigens, suggesting
that MUC16 may serve as a candidate immunogenic hotspot in PDAC [56]. Among
the long-term survivors, intertumoral and lasting circulating T-cell activity is related to
MUC16/CA125 neoantigens [56]. There were 21 and 19 patients who had neoantigens on
PCDHGC5 and PCDHAC2. PCDHGC5 and PCDHAC2 belong to protocadherin (PCDH)
gene clusters. The family of PCDH genes are downregulated in breast cancer tissues and
identified as a new target of aberrant DNA hypermethylation in breast cancer [57].
One limitation of this study is lack of patient specific HLA genotyping. Neoantigens
were predicted based on the peptide-HLA binding affinity scores, available on 729 patients
from a previous study [20]. Neoantigens were currently predicted on peptides bound
to MHC class I molecules only. In the future, we will include MHC class II molecules
in the prediction of neoantigen load. Recent studies detected prominent CD4+ T-cell
responses against immunizing neoantigens in the use of peptide-MHC class I prediction
of neoantigens with unknown reasons [32,33,58]. Improved methods that predict the
immunogenicity of CD8+ antigens and eventually CD4+ antigens would further clarify
these findings and enhance immunogenicity [32,33,58]. Neoantigens derived from driver
mutations in cancer-associated genes will have great potential in immunotherapy. In
melanoma, vemurafenib was shown to improve the rates of response and overall survival
of patients with the BRAF V600E mutation [59–62]. Therefore, future investigation on
neoantigens that are derived from specific mutations may improve personalized therapies
in cancer treatment.
5. Conclusions
In this study, we investigated the correlations between neoantigen expression, clinical
pathological variables, DNA repair gene expression, and assessed the impact of neoantigen
expression and T-cell activation status on patient overall survival in breast cancer. Our
results suggest that neoantigen expression varied across hormone receptor status, molecular
subtype, and disease stage. Neoantigen expression was associated with the expression
levels of 10 DNA repair genes. Moreover, high neoantigen expression was associated with
decreased mortality risk in the whole study samples, T-cell exhaustion subgroup, and PR
positive subgroup, suggesting that neoantigens can serve as potential immunogenic agents
to improve patient survival in breast cancer.
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shared neoantigens stratified by PR status.
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